Skip to content

The randomized controlled multicenter clinical trial of Sodium cromoglicate nasal spray in the treatment of allergic rhinitis

The randomized controlled multicenter clinical trial of Sodium cromoglicate nasal spray in the treatment of allergic rhinitis

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IIR-17013859
Enrollment
Unknown
Registered
2017-12-12
Start date
2008-03-01
Completion date
Unknown
Last updated
2017-12-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

allergic rhinitis

Interventions

Sodium Cromoglicate nasal spray:Sodium Cromoglicate nasal spray
Sodium Cromoglicate nass drops:Sodium Cromoglicate nass drops

Sponsors

Beijing Tongren Hospital, CMU
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. aged 18 to 65 years old, men and women not limited; 2. in the diagnosis of allergic rhinitis patients; 3. above at least two main symptoms, course should be in more than one year (including I); 4. four weeks did not accept antihistamine drugs and glucocorticoids treatment; 5. allergen skin test for at least the main (ShiShi) or (ShiShi) above; 6. volunteered for the clinical trials, and signed informed consent.

Exclusion criteria

Exclusion criteria: 1. pregnancy or recent preparation of pregnant women, lactation women; 2. is associated with severe primary diseases such as heart, liver, kidney, hematopoietic system and other important organs and systems (ALT. AST. BUN is 1.5 times higher than the upper limit of normal value, and C R is 1.2 times higher than the upper limit of normal value). 3. non allergic rhinitis; 4. Complicated with respiratory infection; 5. combined with nerve and mental illness that could not cooperate or unwilling to cooperate. 6. was allergic to the drugs known in this trial. Antiallergic drugs were used around; 7. had participated in other clinical trials within 3 months.

Design outcomes

Primary

MeasureTime frame
symptoms;

Countries

China

Contacts

Public ContactXin Ni

Beijing Tongren Hospital,CMU

gaonaeent@126.com+86 010-58265788

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026